GIP/GLP-1 receptor agonist
Tirzepatide
Also: Mounjaro · Zepbound
Short answer
Tirzepatide is a Regulatory status: FDA-approved. An FDA-approved drug product exists for at least one indication. Approved products: Mounjaro, Zepbound.
Evidence ladder — counts appear as reviewed claims are published
Weakest to strongest. Hover a level to see what it means.
Mechanism of action
In editorial review
Receptor interactions, pathways and proposed mechanisms, with the evidence level for each. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →Research
In editorial review
Human, animal and laboratory studies, summarised in our own words with population, design, findings and limitations. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →Safety
In editorial review
Documented adverse effects, contraindications, interactions and what remains unknown. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →Regulatory timeline
FDA-approvedDated, sourced events. Advisory committee votes and 503A bulks-list actions are distinct from drug approval under section 505 of the FD&C Act.
No regulatory events recorded for Tirzepatide yet.
Clinical trials
In editorial review
Registered studies synced from ClinicalTrials.gov: phase, status, enrollment and whether results have been posted. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →References
In editorial review
Every source cited on this page, with links to PubMed, ClinicalTrials.gov and FDA records. Each statement is stored as a cited claim and must pass reviewer approval before it appears here — we publish nothing unsourced.
How claims are reviewed →Changelog
- 2026-11-02Profile created with identification and regulatory timeline. Scientific sections entered editorial review.